Published in Drug Week, September 8th, 2006
The application of pharmacogenomics in drug development is widespread today in differing degrees of intensity. Pharmacogenomics has recently seen an inflection point that pharmaceutical and biotechnology companies need and want to understand, according to the report. Given recent issues with Cox-2 inhibitors and anti-depressants, the U.S. Food and Drug Administration (FDA) is increasingly focused on bringing personalized medicine to this area. Advances in patents and technology are occurring at a faster rate than ever before....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.